As managing partner with UTC Reference Laboratories, Patrick Ridgeway oversees the development of molecular testing technologies and related direct-to-consumer reports. He owns the intellectual property for two such reports that inform the individual about his or her unique genetic makeup, the knowledge of which can inform future health and wellness choices. Also involved in developing pharmacogenomic and drug metabolism testing technologies, Patrick Ridgeway and his company to aim reduce the need for extensive and costly care resulting from adverse drug reactions

Particularly focused on women's health, Patrick Ridgeway has introduced genetic testing for birth defects, pregnancy risks, breast and ovarian cancers. He adds these innovations to a gynecological product portfolio that also includes bio-identical hormone replacement therapy, or BHRT, and non-surgical vaginal rejuvenation. Over the past four years, these and the company's other developments have generated more than $500 million in sales.

Patrick Ridgeway comes to this success with 25 years of experience in medical technology sales. He earned President's Club honors at St. Jude Medical, Medtronic, and Boston Scientific, having begun his career with a Rookie of the Year award as a representative of Specialty Surgical Instrumentation.